Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 9/20 | 0.62 |
| ▸ | CDK1 | P06493 | 3/20 | 0.62 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.50 |
| ▸ | SYK | P43405 | 7/20 | 0.49 |
| ▸ | CDK4 | P11802 | 2/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | BCR | P11274 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.48 |
| ▸ | CDKL1 | Q00532 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1447493 | 0.92 | CDK2 (0.57) | CDK2CDK1SYKCDK4ABL1 | |
| SCHEMBL1448361 | 0.90 | CDK2 (0.55) | CDK2CDK1SYKCDK4 | |
| SCHEMBL1447113 | 0.89 | CDK2 (0.74) | CDK2CDK1CDK4KCNH2 | |
| SCHEMBL1447533 | 0.87 | CDK2 (0.82) | CDK2CDK1CDK4KCNH2CDKL1 | |
| SCHEMBL1447537 | 0.85 | CDK2 (0.61) | CDK2CDK1NUAK1SYKCDK4 | |
| SCHEMBL1447825 | 0.84 | CDK2 (0.77) | CDK2CDK1CDK4KCNH2CDKL1 | |
| SCHEMBL3541350 | 0.81 | CDK2 (0.62) | CDK2CDK1NUAK1SYKCDK4 | |
| SCHEMBL1447799 | 0.80 | CDK2 (0.66) | CDK2CDK1SYKCDK4KCNH2 | |
| SCHEMBL1447162 | 0.80 | CDK2 (0.69) | CDK2CDK1CDK4KCNH2 | |
| SCHEMBL1447609 | 0.80 | CDK2 (0.75) | CDK2CDK1CDK4KCNH2CDKL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2301928-A1 | Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders | AstraZeneca AB (SE) | 2011-03-30 | — | — | EP | disclosed |